Southampton, UK ? 30 April 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it has received approvals to extend the SG016 trial to patients with SARS-CoV-2 in the home environment. The objective is to initiate dosing with SNG001 (or placebo) earlier in the infection cycle, and before severe lower respiratory tract symptoms have developed. In due course, details of the design, implementation and timing of this novel study will be disclosed more fully. The treatment of patients in the hospital setting in the SG016 study is progressing well, with more than 75 patients out of the target 100 now dosed with Synairgen?s whollyowned drug SNG001 or placebo. Results from this part of the study are still expected in June 2020. For further enquiries, please contact: Synairgen plc Richard Marsden, Chief Executive Officer John Ward, Finance Director Tel: + 44 (0) 23 8051 2800 finnCap Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance) Alice Lane, Manasa Patil (ECM) Tel: + 44 (0) 20 7220 0500 Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser synairgen@consilium-comms.com Tel: +44 (0) 20 3709 5700 Notes for Editors About Synairgen Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com